255 related articles for article (PubMed ID: 24619359)
1. Classification of a frameshift/extended and a stop mutation in WT1 as gain-of-function mutations that activate cell cycle genes and promote Wilms tumour cell proliferation.
Busch M; Schwindt H; Brandt A; Beier M; Görldt N; Romaniuk P; Toska E; Roberts S; Royer HD; Royer-Pokora B
Hum Mol Genet; 2014 Aug; 23(15):3958-74. PubMed ID: 24619359
[TBL] [Abstract][Full Text] [Related]
2. The tumor suppressor WT1 drives progenitor cell progression and epithelialization to prevent Wilms tumorigenesis in human kidney organoids.
Waehle V; Ungricht R; Hoppe PS; Betschinger J
Stem Cell Reports; 2021 Sep; 16(9):2107-2117. PubMed ID: 34450039
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy and terminal skeletal muscle differentiation in WT1-mutant Wilms tumors.
Royer-Pokora B; Beier M; Brandt A; Duhme C; Busch M; de Torres C; Royer HD; Mora J
Cancer Med; 2018 Apr; 7(4):1359-1368. PubMed ID: 29542868
[TBL] [Abstract][Full Text] [Related]
4. A pathologic link between Wilms tumor suppressor gene, WT1, and IFI16.
Kim MK; Mason JM; Li CM; Berkofsky-Fessler W; Jiang L; Choubey D; Grundy PE; Tycko B; Licht JD
Neoplasia; 2008 Jan; 10(1):69-78. PubMed ID: 18231640
[TBL] [Abstract][Full Text] [Related]
5. Deducing the stage of origin of Wilms' tumours from a developmental series of Wt1-mutant mice.
Berry RL; Ozdemir DD; Aronow B; Lindström NO; Dudnakova T; Thornburn A; Perry P; Baldock R; Armit C; Joshi A; Jeanpierre C; Shan J; Vainio S; Baily J; Brownstein D; Davies J; Hastie ND; Hohenstein P
Dis Model Mech; 2015 Aug; 8(8):903-17. PubMed ID: 26035382
[TBL] [Abstract][Full Text] [Related]
6. CTNNB1 mutations and overexpression of Wnt/beta-catenin target genes in WT1-mutant Wilms' tumors.
Li CM; Kim CE; Margolin AA; Guo M; Zhu J; Mason JM; Hensle TW; Murty VV; Grundy PE; Fearon ER; D'Agati V; Licht JD; Tycko B
Am J Pathol; 2004 Dec; 165(6):1943-53. PubMed ID: 15579438
[TBL] [Abstract][Full Text] [Related]
7. Ubiquitin specific protease 18 (Usp18) is a WT1 transcriptional target.
Shahidul Makki M; Cristy Ruteshouser E; Huff V
Exp Cell Res; 2013 Mar; 319(5):612-22. PubMed ID: 23291318
[TBL] [Abstract][Full Text] [Related]
8. Biochemical and functional interaction between ZNF224 and ZNF255, two members of the Kruppel-like zinc-finger protein family and WT1 protein isoforms.
Florio F; Cesaro E; Montano G; Izzo P; Miles C; Costanzo P
Hum Mol Genet; 2010 Sep; 19(18):3544-56. PubMed ID: 20591825
[TBL] [Abstract][Full Text] [Related]
9. WT1 modulates apoptosis by transcriptionally upregulating the bcl-2 proto-oncogene.
Mayo MW; Wang CY; Drouin SS; Madrid LV; Marshall AF; Reed JC; Weissman BE; Baldwin AS
EMBO J; 1999 Jul; 18(14):3990-4003. PubMed ID: 10406804
[TBL] [Abstract][Full Text] [Related]
10. Wilms tumour histology is determined by distinct types of precursor lesions and not epigenetic changes.
Fukuzawa R; Anaka MR; Heathcott RW; McNoe LA; Morison IM; Perlman EJ; Reeve AE
J Pathol; 2008 Aug; 215(4):377-87. PubMed ID: 18484682
[TBL] [Abstract][Full Text] [Related]
11. Changes in WT1 splicing are associated with a specific gene expression profile in Wilms' tumour.
Baudry D; Faussillon M; Cabanis MO; Rigolet M; Zucker JM; Patte C; Sarnacki S; Boccon-Gibod L; Junien C; Jeanpierre C
Oncogene; 2002 Aug; 21(36):5566-73. PubMed ID: 12165855
[TBL] [Abstract][Full Text] [Related]
12. WT1 induces apoptosis through transcriptional regulation of the proapoptotic Bcl-2 family member Bak.
Morrison DJ; English MA; Licht JD
Cancer Res; 2005 Sep; 65(18):8174-82. PubMed ID: 16166292
[TBL] [Abstract][Full Text] [Related]
13. WT1-p53 interactions in insulin-like growth factor-I receptor gene regulation.
Idelman G; Glaser T; Roberts CT; Werner H
J Biol Chem; 2003 Jan; 278(5):3474-82. PubMed ID: 12444079
[TBL] [Abstract][Full Text] [Related]
14. The Wilms tumor suppressor-1 target gene podocalyxin is transcriptionally repressed by p53.
Stanhope-Baker P; Kessler PM; Li W; Agarwal ML; Williams BR
J Biol Chem; 2004 Aug; 279(32):33575-85. PubMed ID: 15155752
[TBL] [Abstract][Full Text] [Related]
15. The many facets of the Wilms' tumour gene, WT1.
Hohenstein P; Hastie ND
Hum Mol Genet; 2006 Oct; 15 Spec No 2():R196-201. PubMed ID: 16987884
[TBL] [Abstract][Full Text] [Related]
16. Wilms Tumor Suppressor, WT1, Cooperates with MicroRNA-26a and MicroRNA-101 to Suppress Translation of the Polycomb Protein, EZH2, in Mesenchymal Stem Cells.
Akpa MM; Iglesias D; Chu L; Thiébaut A; Jentoft I; Hammond L; Torban E; Goodyer PR
J Biol Chem; 2016 Feb; 291(8):3785-95. PubMed ID: 26655220
[TBL] [Abstract][Full Text] [Related]
17. Sequential WT1 and CTNNB1 mutations and alterations of beta-catenin localisation in intralobar nephrogenic rests and associated Wilms tumours: two case studies.
Fukuzawa R; Heathcott RW; More HE; Reeve AE
J Clin Pathol; 2007 Sep; 60(9):1013-6. PubMed ID: 17172473
[TBL] [Abstract][Full Text] [Related]
18. Genomic imprinting at the WT1 gene involves a novel coding transcript (AWT1) that shows deregulation in Wilms' tumours.
Dallosso AR; Hancock AL; Brown KW; Williams AC; Jackson S; Malik K
Hum Mol Genet; 2004 Feb; 13(4):405-15. PubMed ID: 14681303
[TBL] [Abstract][Full Text] [Related]
19. Wilms tumor cells with WT1 mutations have characteristic features of mesenchymal stem cells and express molecular markers of paraxial mesoderm.
Royer-Pokora B; Busch M; Beier M; Duhme C; de Torres C; Mora J; Brandt A; Royer HD
Hum Mol Genet; 2010 May; 19(9):1651-68. PubMed ID: 20106868
[TBL] [Abstract][Full Text] [Related]
20. Upregulation of c-MYC in WT1-mutant tumors: assessment of WT1 putative transcriptional targets using cDNA microarray expression profiling of genetically defined Wilms' tumors.
Udtha M; Lee SJ; Alam R; Coombes K; Huff V
Oncogene; 2003 Jun; 22(24):3821-6. PubMed ID: 12802290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
